Kexing Biopharm Co., Ltd. (SHA:688136)
China · Delayed Price · Currency is CNY 34.22
+0.58 (1.72%)
Jan 23, 2026, 3:00 PM CST
Kexing Biopharm Market Cap
Kexing Biopharm has a market cap or net worth of 6.66 billion as of January 23, 2026. Its market cap has increased by 72.28% in one year.
Market Cap
6.66B
Enterprise Value
7.45B
Revenue
1.52B
Ranking
n/a
PE Ratio
54.28
Stock Price
34.22
Market Cap Chart
Since December 14, 2020, Kexing Biopharm's market cap has decreased from 8.15B to 6.66B, a decrease of -18.22%. That is a compound annual growth rate of -3.86%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 22, 2026 | 6.66B | 6.22% |
| Dec 31, 2025 | 6.27B | 45.13% |
| Dec 31, 2024 | 4.32B | 7.17% |
| Dec 29, 2023 | 4.03B | -5.31% |
| Dec 30, 2022 | 4.26B | -24.16% |
| Dec 31, 2021 | 5.62B | -30.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 14, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GemPharmatech | 7.42B |
| Suzhou Fengbei Biotech Stock | 7.26B |
| Beijing Konruns Pharmaceutical | 6.93B |
| R&G PharmaStudies | 6.68B |
| PharmaResources (Shanghai) | 6.50B |
| Jiangsu Bioperfectus Technologies | 6.48B |
| Xiangxue Pharmaceutical | 6.43B |
| Wuhan Hvsen Biotechnology | 6.35B |